Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05271552 · ClinicalTrials.gov registry record · Phase 3
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
A Phase 3 study, sponsored by BioXcel Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 151
- Enrollment target
NCT05271552 is a Phase 3 study that has completed, run by BioXcel Therapeutics. The registered enrollment target is 151 participants.
The verdict
NCT05271552, a Phase 3 study, has completed, sponsored by BioXcel Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 151 participants
- Enrollment target
Study Summary
A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed \[PRN\]), for a maximum of 28 doses within a 12-week treatment period.
Interventions
- DRUG Matching Placebo
- DRUG BXCL501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2022-04-27 |
| Est. Completion | 2023-04-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05271552
The ClinicalTrials.gov registry entry for NCT05271552 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioXcel Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT05271552 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05271552 about?
NCT05271552 is a clinical study titled "Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)". A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed \[PRN\]), for a maximum of 28 doses within a 12-week treatment period.
What is the current status of trial NCT05271552?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 151 participants. The study started on 2022-04-27. Estimated completion is 2023-04-21.
What interventions are being tested in trial NCT05271552?
The interventions under investigation include: Matching Placebo (DRUG), BXCL501 (DRUG).
Who is sponsoring clinical trial NCT05271552?
This trial is sponsored by BioXcel Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.